证券代码：603259 证券简称：药明康德 公告编号：临 2025-043 无锡药明康德新药开发股份有限公司 关于 2025 年第一次以集中竞价交易方式首次回购公司股份 暨股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2025/3/18 □用于转换公司可转债 □为维护公司价值及股东权益 | 累计已回购股数 | 302,500股 | | --- | --- | | 累计已回购股数占总股本比例 | 0.0105% | | 累计已回购金额 | 20,008,386.00元 | | 实际回购价格区间 | 65.54元/股~67.36元/股 | 一、 回购股份的基本情况 无锡药明康德新药开发股份有限公司（以下简称"公司"）于 2025 年 3 月 17 日召开第三届董事会第十七次会议暨 2024 年年度董事会，并于 2025 年 4 月 29 日 召开 2024 年年度股东大会，审议通过《关于 2025 年以集中竞价交易方式回购公 司 A 股股份的议案》，同意使用自有资金和自筹资金 ...

Core Viewpoint - WuXi AppTec, a leading CRO company, has completed a share repurchase of approximately 1 billion yuan, marking its second repurchase in 2025, with a total of 40 billion yuan repurchased since 2024 [1][2][3] Group 1: Share Repurchase - The company has completed its second share repurchase in 2025, buying back 15.7754 million shares at an average price of 63.39 yuan per share, totaling around 1 billion yuan [2] - Since 2024, WuXi AppTec has conducted five "cancellation-style" repurchases, with four completed, amounting to a total of 40 billion yuan [1][3] - The purpose of these repurchases is to reduce the company's registered capital and enhance shareholder value [2][3] Group 2: Financial Performance - Since its IPO in 2018, WuXi AppTec has achieved a cumulative net profit of 43.716 billion yuan and a total cash dividend of 13.93 billion yuan, with a dividend payout ratio of 31.87% [1][3] - In Q1 2025, the company reported a revenue of 9.65 billion yuan, a year-on-year increase of approximately 21%, and a net profit of 3.673 billion yuan, reflecting a growth of 89.06% [4][5] - The company’s order backlog as of March 2025 stands at 52.33 billion yuan, a year-on-year increase of 47.1% [6]

Group 1: Stock Resumption and Suspension - Huasheng Co. plans to acquire 100% of Yixin Technology, leading to stock resumption [1] - Tianyi Ma intends to purchase 100% equity of intelligent self-service equipment company Xingyun Kaiwu, resulting in stock resumption [1] - Guotou Zhonglu is set to acquire controlling interest in Electronic Institute, and will continue to suspend trading [1] - Zhongda An's controlling shareholder is planning to issue shares to specific targets, causing a change in control and continued suspension of trading [1] Group 2: Share Buybacks and Equity Transfers - Inspur Information plans to repurchase shares worth 200 million to 300 million yuan to reduce registered capital [2] - WuXi AppTec has completed a 1 billion yuan share buyback and plans to cancel the shares [2] - Shanghai Mechanical and Electrical's controlling shareholder intends to transfer 5% of shares through an agreement [2] - Cambrian has adjusted the upper limit for share repurchase price to no more than 818.87 yuan per share [2] Group 3: Daily Operations and External Investments - JinkoSolar has achieved a record conversion efficiency of 27.02% for its 182N-type high-efficiency monocrystalline silicon cells [3] - Wanyi Technology has established a joint laboratory for the development of key vacuum measurement equipment for nuclear fusion [3] - Hailianxun's application for a stock swap merger with Hangqilun has been accepted by the Shenzhen Stock Exchange [3] - Baotai has signed a licensing and production agreement with SteinCares for BAT2406 (Dupilumab) injection [3] - Tailinwei's sales of edge AI new products reached a scale of 10 million yuan in the second quarter [3] - Guiguan Electric is investing 9.5 billion yuan in the construction of a photovoltaic project [3] - Songsheng Co. has signed a contract with Chongqing Jingang Transmission for the development of robotic harmonic reducers and intelligent joint technology [3] - Huilv Ecology's silicon optical single-mode products have entered mass production [3] - Hongmian Co. plans to acquire 39.99% equity of Asia Foods for 90.28 million yuan and accept 60% voting rights delegation [3]

SHANGHAI, June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec's near-term science-based emissions reduction targets. The validation of these targets affirms that the Company's planned reduction in greenhouse gas (GHG) emissions aligns with the goal of limiting global temperature ris ...

Core Insights - As of June 12, a total of 159 stocks reached their 52-week highs, with HPC HOLDINGS (01742), China Ecotourism (01371), and Yunfeng Financial (00376) leading the high rate at 51.28%, 43.10%, and 35.00% respectively [1][2] Stock Performance Summary - **Top Performers**: - HPC HOLDINGS (01742) closed at 0.084 with a peak of 0.118, achieving a high rate of 51.28% [2] - China Ecotourism (01371) closed at 0.670 with a peak of 0.830, achieving a high rate of 43.10% [2] - Yunfeng Financial (00376) closed at 2.730 with a peak of 3.510, achieving a high rate of 35.00% [2] - **Other Notable Stocks**: - Jiuyuan Gene (02566) reached a high rate of 23.08% [2] - Zhangli International (01693) reached a high rate of 21.29% [2] - China Biopharmaceutical (01177) reached a high rate of 16.46% [2] - **Additional Stocks with Significant High Rates**: - Beike Micro (02149) at 14.29% [2] - Rongchang Bio (09995) at 14.16% [2] - Baosaitou-B (02315) at 12.86% [2] - SF Technology (09699) at 12.63% [2] 52-Week Low Summary - **Top Decliners**: - Baide International (02668) reached a low rate of -22.22% [6] - Zhizhong International (06063) reached a low rate of -14.89% [6] - Congyu Zhinu (00875) reached a low rate of -9.23% [6] - **Other Notable Decliners**: - China Greenland Boda Green (01253) at -7.69% [6] - New Qian'an (02573) at -7.66% [6] - Aobang Construction (01615) at -3.85% [6]

Core Insights - The article highlights the top and bottom AH share premium rates as of June 10, with Northeast Electric (00042) leading at a premium rate of 958.82% and Ningde Times (03750) at the bottom with -1.75% [1][2]. Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 958.82% with H-share priced at 0.255 HKD and A-share at 2.25 CNY [2]. - Hongye Futures (03678) follows with a premium rate of 271.39%, H-share at 3.390 HKD and A-share at 10.51 CNY [2]. - Andeli Juice (02218) ranks third with a premium rate of 268.02%, H-share at 15.980 HKD and A-share at 49.1 CNY [2]. Group 2: Bottom AH Share Premium Rates - Ningde Times (03750) has a premium rate of -1.75%, with H-share at 299.600 HKD and A-share at 245.75 CNY [2]. - WuXi AppTec (02359) has a premium rate of 5.05%, H-share at 74.000 HKD and A-share at 64.9 CNY [2]. - China Merchants Bank (03968) has a premium rate of 5.13%, H-share at 50.900 HKD and A-share at 44.67 CNY [2]. Group 3: Top Share Deviation Values - BYD Company (01211) leads with a deviation value of 202.33%, H-share at 135.600 HKD and A-share at 353.13 CNY [2]. - Longpan Technology (02465) follows with a deviation value of 30.49%, H-share at 6.910 HKD and A-share at 15.33 CNY [2]. - Yanzhou Coal Mining (01171) has a deviation value of 11.04%, H-share at 8.250 HKD and A-share at 12.79 CNY [2]. Group 4: Bottom Share Deviation Values - China Shipbuilding Defense (00317) has the lowest deviation value at -46.55%, H-share at 13.360 HKD and A-share at 24.9 CNY [3]. - Zhejiang Shibao (01057) follows with -37.20%, H-share at 4.650 HKD and A-share at 11.93 CNY [3]. - Junshi Biosciences (01877) has a deviation value of -35.39%, H-share at 24.600 HKD and A-share at 37 CNY [3].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年6月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年6月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 ...

Group 1 - The pharmaceutical sector has recently experienced a significant pullback, with the innovative drug concept seeing a net outflow of nearly 2.5 billion yuan in A-shares [1] - The Tianhong Innovative Drug ETF (517380) reached a new high for the year before experiencing a substantial decline, dropping 2.75% with a trading volume of 22 million yuan, and most constituent stocks fell nearly 5% [1] - The Tianhong Innovative Drug ETF is the only product tracking the Hang Seng-Hu-Shen-Hong Kong Innovative Drug Selected 50 Index, which includes leading innovative drug companies from the three markets [1] Group 2 - Dongwu Securities predicts that 2025 will mark the explosive growth of China's innovative drug industry, driven by three core factors: significant BD transactions, profitability turning points for leading companies, and an improving policy environment [2] - Guosheng Securities acknowledges short-term trading pullback risks but emphasizes the solid underlying logic and clear trends in the innovative drug sector, maintaining a positive outlook for the innovative drug bull market [2] - The market size of China's innovative drugs is expected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [2]

Group 1 - The market experienced a rebound on June 4, with the ChiNext Index leading the gains. The total trading volume in the Shanghai and Shenzhen markets reached 1.15 trillion yuan, an increase of 11.6 billion yuan compared to the previous trading day [1] - The innovative drug concept remained active, with the Tianhong Innovative Drug ETF (517380) closing up 2.34%, reaching a peak price of 0.660 yuan, the highest since November 2023, and achieving a trading volume of nearly 20 million yuan, a two-year high [1] - The Tianhong Innovative Drug ETF (517380) has seen a year-to-date increase of 25.96% as of June 4, ranking first among all industry ETFs in the market [1] Group 2 - Changjiang Securities indicated that the valuation level of domestic innovative drugs is low, and some products have the potential to be the best in their class globally, supporting the outlook for innovative drugs to expand internationally and achieve premium valuations [2] - Guojin Securities emphasized that innovative drugs and certain semi-innovative drugs are key investment focuses, with upcoming policy changes and data releases expected to catalyze stock price movements [2] - Huafu Securities reported that the total transaction amount for innovative drug BD from 2020 to 2024 increased from 9.2 billion USD to 52.3 billion USD, with the upfront payment amount rising from 600 million USD to 4.1 billion USD [2]